While the total CD8+ population remained unchanged with TLR5 agonist monotherapy and combination therapy, the activated CD8+ T cell subset expressing cytokine IFN-γ increased significantly in both TLR agonist-treated groups (Fig. 4A, B), in both the tumor and spleen. The gene discussed is CD8A; the disease is neoplasm.